Article
PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS).
Circulation - 20 Mar 2018
Mefford Matthew T, Rosenson Robert S, Cushman Mary, Farkouh Michael E, McClure Leslie A, Wadley Virginia G, Irvin Marguerite R, Bittner Vera, Safford Monika M, Somaratne Ransi, Monda Keri L, Muntner Paul, Levitan Emily B
Abstract excerpt
BACKGROUND: Despite concerns about adverse neurocognitive events raised by prior trials, pharmacological PCSK9 (proprotein convertase subtilisin/kexin type-9) inhibition was not associated with neurocognitive effects in a recent phase 3 randomized trial. PCSK9 loss-of-function (LOF) variants that result in lifelong exposure to lower levels of low-density lipoprotein cholesterol can provide information on the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.